This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Stocks Set to Soar on Bullish Earnings

Cubist Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Another possible earnings short-squeeze trade is biotechnology and drugs player Cubist Pharmaceuticals (CBST), which is set to release its numbers on Thursday after the market close. This company is focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. Wall Street analysts, on average, expect Cubist Pharmaceuticals to report revenue of $225.47 million on earnings of 46 cents per share.

Last week, Jefferies issues some comments on Cubist saying that the market has been pricing in little to no value for its Phase 3 drug candidates. Jefferies also said it views the current valuation for Cubist as attractive, and kept its buy rating on the stock with a $50 price target.

The current short interest as a percentage of the float for Cubist Pharmaceuticals is very high at 15.1%. That means that out of the 63.04 million shares in the tradable float, 9.52 million shares are sold short by the bears. This is the type of short interest that can produce explosive moves higher on a stock if the company can deliver what the bulls are looking for.

>>5 Biotech Stocks Under $10 Set to Soar

From a technical perspective, CBST is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock had been downtrending hard for the last four months, with shares falling from a high of $44.95 to a recent low of $36.73 a share. During that downtrend, shares of CBST have been making mostly lower highs and lower lows, which is bearish technical price action. That said, this stock has started to lift off that low of $36.73 a share and rip back above both its 50-day and 200-day moving averages.

If you're in the bull camp on CBST, then I would wait until after they report earnings and look for long-biased trades if this stock triggers a near-term breakout trade above some overhead resistance levels at $41.67 to $43 a share with high volume. Look for volume on that move that registers near or above its three-month average volume of 810,070 shares. If we get that move, then CBST will have a great chance of re-testing and possibly taking out its next significant overhead resistance levels at $44 to $44.95 a share. A move over $44.95 would be very bullish since it will mean CBST has entered new 52-week-high territory.

I would simply avoid CBST or look for short-biased trades if after earnings this stock fails to trigger that breakout, and then moves back below its 50-day at $40.21 and its 200-day at $39.98 a share with heavy volume. If we get that move, then CBST could get sold off by the bears all the way down to its recent low of $36.73 a share, or possibly even lower to $34.50 to $33.43 a share.

3 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,067.56 -30.89 -0.18%
S&P 500 2,002.28 -1.09 -0.05%
NASDAQ 4,598.1880 +17.9170 0.39%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs